Screening for lymphoma in patients with uveitis
Screening for Oculocerebral Lymphoma by Identifying the Phenotype Carried by Circulating NK Cells in Patients with Uveitis
This study is testing whether analyzing blood samples can help find out if people with uveitis have a type of cancer called oculocerebral lymphoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 2 sites (Lyon and 1 other locations) |
| Trial ID | NCT05388838 on ClinicalTrials.gov |
What this trial studies
This study aims to identify the presence of oculocerebral lymphoma in patients diagnosed with uveitis by analyzing blood samples. Uveitis is an inflammatory condition that can lead to significant vision loss and may have various underlying causes, including cancer. The study focuses on differentiating between inflammatory and cancerous etiologies to facilitate appropriate treatment. Participants will be categorized based on their specific conditions related to uveitis and lymphoma.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with a diagnosis of uveitis and specific conditions related to ocular lymphoma.
Not a fit: Patients with uveitis who have already been diagnosed with cerebral lymphoma or those without any ocular involvement may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnosis of lymphoma in patients with uveitis, potentially improving treatment outcomes.
How similar studies have performed: While there is limited information on similar studies, the approach of screening for lymphoma in patients with uveitis is relatively novel and may provide new insights into diagnosis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: GENERAL CRITERIA * Male or female over 18 years of age, * Free, informed, written consent signed by the patient and the investigator (at the latest on the day of inclusion) and before any examination required by the research, * Patient affiliated to the social security system or beneficiary of such a system, * Maximum volume of sampling (care + research) per 30-day period to be adapted according to the patient's weight (Order of April 12, 2018 establishing the list of research mentioned in 2° of Article L. 1121-1). SPECIFIC CRITERIA \- Patient affected in one or both eyes: of uveitis with another diagnosis than ocular lymphoma and without cerebral lymphoma (Group 1), or primary ocular lymphoma without brain involvement and never treated (Group 2), or primary ocular lymphoma without brain involvement, treated and considered in remission (IL10 HA level \< 10) (Group 3), or primary ocular lymphoma without brain involvement, and considered in relapse (IL10 HA level \> 30) (Group 4), or cerebral lymphoma with or without ocular involvement and without uveitis (Group 5), or cataract (pre- and post-op), glaucoma, retinal detachment or epiretinal retinal detachment or epiretinal membrane, but no brain damage or uveitis (group 6). Exclusion Criteria: * -GENERAL CRITERIA * Patient participating in an ongoing clinical trial at the time of the inclusion visit, * Pregnant women, women in labor or nursing mothers, * Persons deprived of liberty by a judicial or administrative decision, * Persons under psychiatric care, * Persons admitted to a health or social institution for purposes other than research, * Persons of full age who are subject to a legal protection measure (guardianship, curatorship). SPECIFIC CRITERIA * Patient for whom the diagnosis of ocular or cerebral lymphoma is uncertain, * Patient with another systemic cancer that is evolving or in remission \< 2 years.
Where this trial is running
Lyon and 1 other locations
- Service d'Ophtalmologie, Hôpital de la Croix-Rousse, GHN — Lyon, France (Recruiting)
- Service d'Hématologie Clinique, Hôpital Lyon Sud — Lyon, France (Recruiting)
Study contacts
- Study coordinator: Thibaud MATHIS, Dr
- Email: thibaud.mathis@chu-lyon.fr
- Phone: 4 26 10 93 22
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.